Ligand Pharmaceuticals Inc (LGND) shareholders
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 2,839,251 | 14.50% | 13G (passive) amendment | Sep 30, 2025 |
| Invesco Ltd. | 1,520,911 | 7.60% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Portfolio Management | 1,109,154 | 5.56% | 13G (passive) | Mar 31, 2026 |
| Janus Henderson Group PLC | 1,042,378 | 5.30% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Capital Management | 997,637 | 5.00% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LGND | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,100,996 | – | $980.19M | +139,073 | 0.01% |
| Invesco Ltd. | 1,201,644 | – | $379.83M | +378,040 | 0.03% |
| Vanguard Portfolio Management LLC | 1,138,316 | – | $359.81M | +38,049 | 0.02% |
| Jupiter Topco LLC | 1,040,578 | – | $328.91M | New | 0.13% |
| Vanguard Capital Management LLC | 870,950 | – | $275.30M | +22,861 | 0.01% |
| State Street Corp | 826,539 | – | $261.25M | +47,683 | 0.01% |
| FMR LLC | 762,827 | – | $241.12M | +166,700 | 0.01% |
| Franklin Resources Inc | 752,044 | – | $237.71M | +178,867 | 0.05% |
| Congress Asset Management Co /Ma | 659,911 | – | $208.59M | +155,274 | 1.28% |
| Geode Capital Management, LLC | 589,020 | – | $186.21M | +30,086 | 0.01% |
| Nomura Asset Management International Inc. | 568,371 | – | $179.66M | −4,941 | 0.27% |
| Chicago Capital, LLC | 553,435 | – | $174.94M | −8,240 | 4.21% |
| Stephens Investment Management Group LLC | 475,609 | – | $150.34M | −19,061 | 1.61% |
| Dimensional Fund Advisors LP | 429,314 | – | $135.70M | +4,084 | 0.02% |
| Massachusetts Financial Services Co /Ma/ | 375,762 | – | $118.77M | −35,781 | 0.04% |
| Goldman Sachs Group Inc | 323,245 | – | $102.17M | −57,866 | 0.01% |
| Loomis Sayles & Co L P | 291,805 | – | $92.24M | −61,404 | 0.12% |
| Rice Hall James & Associates, LLC | 270,052 | – | $85.36M | −13,515 | 4.15% |
| Ranger Investment Management, L.P. | 257,596 | – | $81.42M | −10,347 | 5.15% |
| Northern Trust Corp | 257,389 | – | $81.36M | +3,231 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 415 | 23M | 97 / 149 | 114 / 34 | 4M | 1M |
| Q1 2026 | 359 | 21M | 59 / 133 | 115 / 43 | 3M | 1M |
| Q4 2025 | 350 | 21M | 70 / 110 | 116 / 30 | 2M | 2M |
| Q3 2025 | 314 | 21M | 64 / 100 | 103 / 16 | 3M | 1M |
| Q2 2025 | 271 | 19M | 33 / 110 | 88 / 23 | 1M | 1M |
| Q1 2025 | 262 | 19M | 33 / 102 | 86 / 27 | 1M | 1M |
| Q4 2024 | 258 | 18M | 41 / 108 | 62 / 22 | 1M | 1M |
| Q3 2024 | 243 | 18M | 38 / 97 | 53 / 28 | 4M | 1M |
| Q2 2024 | 235 | 17M | 43 / 82 | 73 / 27 | 2M | 2M |
| Q1 2024 | 222 | 17M | 33 / 64 | 71 / 19 | 2M | 1M |
| Q4 2023 | 211 | 16M | 34 / 72 | 71 / 17 | 1M | 1M |
| Q3 2023 | 196 | 16M | 20 / 67 | 77 / 27 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
391 funds held LGND in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LGND | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,207,351 | – | $381.63M | 0.34% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 605,720 | – | $191.46M | 0.01% | Jun 30, 2026 |
| Franklin Dynatech Fund | 550,000 | – | $173.85M | 0.58% | Jun 30, 2026 |
| Invesco Discovery Fund | 519,159 | – | $120.42M | 1.54% | May 31, 2026 |
| iShares Russell 2000 ETF | 515,565 | – | $162.96M | 0.20% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 494,252 | – | $156.23M | 2.63% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 436,817 | – | $138.07M | 0.07% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 385,274 | – | $89.37M | 1.62% | May 29, 2026 |
| Fidelity Small Cap Value Fund | 325,665 | – | $93.64M | 1.71% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 276,594 | – | $87.43M | 0.13% | Jun 30, 2026 |
| Janus Henderson Venture Fund | 275,579 | – | $87.11M | 2.41% | Jun 30, 2026 |
| Congress Small Cap Growth Fund | 271,577 | – | $78.09M | 3.89% | Jul 31, 2026 |
| Vanguard Explorer Fund | 234,250 | – | $67.36M | 0.30% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 229,869 | – | $72.66M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 219,513 | – | $63.12M | 0.19% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Todd C. Davis | Chief Executive Officer, Director | 199,513 | Jul 6, 2026 |
| Andrew Reardon | CLO & Secretary | 31,854 | Nov 4, 2026 |
| Octavio Espinoza | Chief Financial Officer | 48,818 | Aug 14, 2026 |
| Martine Zimmermann | Director | 1,782 | Nov 16, 2026 |
| John W. Kozarich | Director | 42,122 | Nov 16, 2026 |
| Jason Aryeh | Director | 113,476 | Nov 12, 2026 |
| Jason Haas | Director | 3,981 | Aug 14, 2026 |
| Stephen L. Sabba | Director | 33,629 | Jun 18, 2026 |
| John L. Lamattina | Director | 31,071 | Jun 12, 2026 |
| Nancy Ryan Gray | Director | 8,930 | Jun 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Martine Zimmermann Director | Nov 12, 2026 | Sale | −2,000 | $318.17 | $636.34K | 1,782 |
| John W. Kozarich Director | Nov 12, 2026 | Sale(10b5-1 plan) | −500 | $325.00 | $162.50K | 42,122 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −500 | $320.20 | $160.10K | 105,476 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −500 | $320.10 | $160.05K | 105,976 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −10 | $320.02 | $3.20K | 106,476 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −646 | $320.00 | $206.72K | 106,486 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −844 | $320.00 | $270.08K | 107,132 |
| Jason Aryeh Director | Nov 10, 2026 | Sale | −500 | $319.99 | $160.00K | 107,976 |
| Jason Aryeh Director | Nov 4, 2026 | Sale | −282 | $319.99 | $90.24K | 108,476 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −120 | $323.14 | $38.78K | 31,854 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −200 | $321.44 | $64.29K | 31,974 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −320 | $319.97 | $102.39K | 32,174 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −440 | $318.73 | $140.24K | 32,494 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −280 | $317.91 | $89.01K | 32,934 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −80 | $314.58 | $25.17K | 33,214 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −403 | $313.75 | $126.44K | 33,294 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −634 | $312.85 | $198.35K | 33,697 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −520 | $311.72 | $162.09K | 34,331 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −490 | $310.61 | $152.20K | 34,851 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −522 | $309.91 | $161.77K | 35,341 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −708 | $308.43 | $218.37K | 35,863 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Sale(10b5-1 plan) | −283 | $307.39 | $86.99K | 36,571 |
| Andrew Reardon CLO & Secretary | Nov 2, 2026 | Option exercise | +5,000 | $52.27 | $261.35K | 36,854 |
| Jason Aryeh Director | Nov 2, 2026 | Sale | −700 | $320.43 | $224.30K | 108,758 |
| Jason Aryeh Director | Oct 30, 2026 | Sale | −50 | $320.49 | $16.02K | 109,458 |
| Jason Aryeh Director | Oct 30, 2026 | Sale | −1,209 | $320.42 | $387.38K | 109,508 |
| Jason Aryeh Director | Oct 30, 2026 | Sale | −52 | $320.24 | $16.65K | 110,717 |
| Jason Aryeh Director | Oct 30, 2026 | Sale | −50 | $318.23 | $15.91K | 110,769 |
| Jason Aryeh Director | Oct 30, 2026 | Sale | −50 | $317.74 | $15.89K | 110,819 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −17 | $307.74 | $5.23K | 31,854 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −235 | $307.19 | $72.19K | 31,871 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −404 | $306.18 | $123.70K | 32,106 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −1,535 | $304.52 | $467.43K | 32,510 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −1,976 | $303.54 | $599.80K | 34,045 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Sale(10b5-1 plan) | −833 | $302.51 | $251.99K | 36,021 |
| Andrew Reardon CLO & Secretary | Oct 2, 2026 | Option exercise | +340 | $52.27 | $17.77K | 36,854 |
| Martine Zimmermann Director | Sep 22, 2026 | Tax withholding | −115 | $298.50 | $34.33K | 3,782 |
| Martine Zimmermann Director | Sep 10, 2026 | Sale | −1,200 | $285.00 | $342.00K | 3,897 |
| Andrew Reardon CLO & Secretary | Sep 3, 2026 | Sale(10b5-1 plan) | −400 | $288.98 | $115.59K | 36,514 |
| Andrew Reardon CLO & Secretary | Sep 3, 2026 | Sale(10b5-1 plan) | −300 | $283.99 | $85.20K | 41,214 |
| Andrew Reardon CLO & Secretary | Sep 3, 2026 | Sale(10b5-1 plan) | −2,115 | $286.36 | $605.65K | 37,299 |
| Andrew Reardon CLO & Secretary | Sep 3, 2026 | Sale(10b5-1 plan) | −1,800 | $285.17 | $513.31K | 39,414 |
| Andrew Reardon CLO & Secretary | Sep 3, 2026 | Sale(10b5-1 plan) | −385 | $287.53 | $110.70K | 36,914 |
| Jason Haas Director | Aug 12, 2026 | Sale | −7,138 | $292.81 | $2.09M | 3,981 |
| Jason Haas Director | Aug 12, 2026 | Option exercise | +6,138 | $51.56 | $316.48K | 11,119 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Option exercise | +2,869 | $55.75 | $159.95K | 48,818 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Option exercise | +2,074 | $70.04 | $145.26K | 45,949 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Sale(10b5-1 plan) | −31,641 | $292.07 | $9.24M | 27,696 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Option exercise | +7,171 | $57.22 | $410.32K | 55,989 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Option exercise | +3,348 | $68.74 | $230.14K | 59,337 |
| Octavio Espinoza Chief Financial Officer | Aug 12, 2026 | Option exercise | +16,179 | $52.84 | $854.90K | 43,875 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −503 | $289.80 | $145.77K | 43,114 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −356 | $288.75 | $102.80K | 43,617 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −1,214 | $287.77 | $349.35K | 43,973 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −1,032 | $286.80 | $295.98K | 45,187 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −157 | $285.74 | $44.86K | 46,219 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −33 | $284.55 | $9.39K | 46,376 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −105 | $284.14 | $29.83K | 46,409 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Option exercise | +5,000 | $52.27 | $261.35K | 46,514 |
| Andrew Reardon CLO & Secretary | Aug 3, 2026 | Sale(10b5-1 plan) | −409 | $292.82 | $119.76K | 41,514 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ligand Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,586 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jason Aryeh Director | Nov 10, 2026 | 3,000 | $960.08K | Nov 10, 2026 | Secondary Market Purchase |
| Jason Aryeh Director | Nov 4, 2026 | 282 | $90.23K | Nov 4, 2026 | Secondary Market Purchase |
| Jason Aryeh Director | Nov 2, 2026 | 700 | $221.60K | Nov 2, 2026 | Secondary Market Purchase |
| Jason Aryeh Director | Oct 30, 2026 | 1,209 | $385.19K | Oct 30, 2026 | Restricted Stock |
| Jason Aryeh Director | Oct 30, 2026 | 202 | $64.74K | Oct 30, 2026 | Open Market Purchase |
| Martine Zimmermann Director | Sep 10, 2026 | 1,200 | $342.00K | Sep 10, 2026 | Restricted Stock |
| Andrew Reardon Officer | Sep 3, 2026 | 15,000 | $4.30M | Sep 3, 2026 | Exercise of Stock Options |
| Octavio Espinoza Officer | Aug 12, 2026 | 31,641 | $9.14M | Aug 12, 2026 | Exercise of Stock Options |
| Jason Haas Director | Aug 12, 2026 | 7,138 | $2.09M | Aug 12, 2026 | Stock Option Exercise |
| Andrew Reardon Officer | Jul 1, 2026 | 10,000 | $3.16M | Jul 1, 2026 | Exercise of Stock Options |
| Stephen L. Sabba Director | Jun 16, 2026 | 2,145 | $544.83K | Jun 16, 2026 | Stock Option Exercise |
| Jason Haas Director | Jun 12, 2026 | 6,461 | $1.65M | Jun 12, 2026 | Stock Option Exercise |
| Jason Aryeh Director | Jun 11, 2026 | 4,500 | $1.12M | Jun 11, 2026 | Open Market Purchase |
| Jason Aryeh Director | Jun 10, 2026 | 5,000 | $1.25M | Jun 10, 2026 | Open Market Purchases |
| John L. Lamattina Director | Jun 10, 2026 | 4,519 | $1.13M | Jun 10, 2026 | Restricted Stock |
Congress trades
5 trades in Ligand Pharmaceuticals reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | May 29, 2026 | $1K–15K | Jun 8, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Bought | Jan 15, 2026 | $1K–15K | Feb 13, 2026 |
| Gilbert Cisneros CA31 | Bought | Jan 5, 2026 | $1K–15K | Feb 13, 2026 |
| Lamar Smith TX21 | Bought | Dec 1, 2017 | $1K–15K | Jan 9, 2018 |
See a number that looks wrong?